Latest Conference Articles

The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.

Perioperative Vorasidenib and Ivosidenib Remain Effective, Safe in IDH1+ Diffuse Glioma

November 25th 2024, 9:34pm

Society for Neuro-Oncology Annual Meeting

Perioperative vorasidenib or ivosidenib demonstrated sustained clinical benefit in patients with predominantly non-enhancing IDH1-mutant diffuse glioma.

Mirdametinib Improves HRQOL in Adult and Pediatric Patients With NF1-PN

November 25th 2024, 6:30pm

Society for Neuro-Oncology Annual Meeting

Mirdametinib led to sustained, significant, and clinically meaningful improvements in HRQOL in adults and children with NF1-PN.

Dr Kumethaker on CSF Tumor Detection in Breast Cancer or NSCLC with Leptomeningeal Disease

November 25th 2024, 1:11pm

Society for Neuro-Oncology Annual Meeting

Priya U. Kumthekar, MD, discusses the use of a novel diagnostic platform to detect CSF tumor cells in patients with leptomeningeal disease.

Dr Schiff on PFS and OS Data With Temozolomide Plus Radiation in Grade II Glioma

November 25th 2024, 12:58pm

Society for Neuro-Oncology Annual Meeting

David Schiff, MD, discusses PFS and OS data for radiation with or without temozolomide in patients with grade II glioma.

Larotrectinib Induces Rapid, Durable Responses in Pediatric Patients With TRK Fusion+ CNS Tumors

November 24th 2024, 5:55pm

Society for Neuro-Oncology Annual Meeting

Larotrectinib produced rapid and durable responses and a high DCR in pediatric patients with TRK fusion–positive primary central nervous system tumors.

Dr Gershon on Deep Responses With Mirdametinib in NF1-PN

November 24th 2024, 12:00am

Society for Neuro-Oncology Annual Meeting

Timothy Gershon, MD, PhD, discusses an analysis of patients with NF1-PN who achieved deep responses with mirdametinib in the phase 2b ReNeu study.

Dr Hansford on HRQOL Outcomes With Tovorafenib in Pediatric BRAF-Altered Low-Grade Glioma

November 23rd 2024, 10:49pm

Society for Neuro-Oncology Annual Meeting

Jordan R. Hansford, MD, discusses health-related quality-of-life outcomes with tovorafenib in pediatric patients with BRAF-altered low-grade glioma.

Vorasidenib Shows Consistent Efficacy With Manageable Safety in IDH1/2-Mutant Diffuse Glioma

November 23rd 2024, 7:37pm

Society for Neuro-Oncology Annual Meeting

Updated INDIGO data reveal that vorasidenib continues to showcase improved efficacy over placebo in patients with IDH1/2-mutated diffuse glioma.

Tovorafenib Leads to Durable Off-Treatment Responses in Pediatric BRAF-Altered R/R Low-Grade Glioma

November 23rd 2024, 5:55pm

Society for Neuro-Oncology Annual Meeting

Tovorafenib generated durable drug holiday responses in pediatric patients with BRAF-altered relapsed/refractory low-grade glioma.

NanO2 Plus Radiation/Temozolomide Is Under Exploration in Newly Diagnosed Glioblastoma

November 23rd 2024, 5:29pm

Society for Neuro-Oncology Annual Meeting

Early safety findings from the phase 2b RESTORE study (NCT03862430) of NanO2 plus radiation and temozolomide in newly diagnosed glioblastoma were shared.

Dr Elder on the Initial Safety Profile of IGV-001 in Newly Diagnosed Glioblastoma

November 23rd 2024, 12:12am

Society for Neuro-Oncology Annual Meeting

J. Bradley Elder, MD, discusses blinded early-safety data from a phase 2b trial of IGV-001 in patients with newly diagnosed glioblastoma.

Dr Lukas on Survival Outcomes With Eflornithine in IDH-Mutant Anaplastic Astrocytoma

November 22nd 2024, 11:54pm

Society for Neuro-Oncology Annual Meeting

Rimas V. Lukas, MD, discusses the efficacy of eflornithine plus lomustine in recurrent IDH-mutant anaplastic astrocytoma per 2021 WHO diagnostic criteria.

IGV-001 Showcases Positive Benefit-Risk Profile in Newly Diagnosed Glioblastoma

November 22nd 2024, 9:25pm

Society for Neuro-Oncology Annual Meeting

IGV-001, an autologous cell immunotherapy, demonstrated an acceptable safety profile in patients with newly diagnosed glioblastoma.

Dr Reidy-Lagunes on the Evolving NET Treatment Paradigm

November 22nd 2024, 9:25pm

PER® Chemotherapy Foundation Symposium (CFS)

Diane Reidy-Lagunes, MD, discusses key trials that have expanded the treatment paradigm for patients with neuroendocrine tumors.

Dr Janjigian on the FDA Approval of Zolbetuximab for CLDN18.2+ Gastric/GEJ Adenocarcinoma

November 22nd 2024, 1:45pm

PER® Chemotherapy Foundation Symposium (CFS)

Yelena Y. Janjigian, MD, discusses the significance of the FDA approval of zolbetuximab plus chemotherapy for HER2–, CLDN18.2+ gastric/GEJ adenocarcinoma.

Dr Caimi on Early Data for LMY-920 in R/R B-Cell NHL

November 19th 2024, 7:05pm

SITC Meeting

Paolo Caimi, MD, discusses the rationale behind evaluating LMY-920, a novel BAFF CAR T-cell therapy, in relapsed/refractory non-Hodgkin lymphoma.

Navigating a “Sea Change” in Frontline Urothelial Carcinoma Treatment

November 16th 2024, 11:00am

PER® Chemotherapy Foundation Symposium (CFS)

David H. Aggen, MD, PhD, details the evolving landscape of treating patients with urothelial carcinoma.

Dr Scalici on Data for IMNN-001 Plus SOC Chemotherapy in Advanced Ovarian Cancer

November 15th 2024, 8:42pm

SITC Meeting

Jennifer Scalici, MD, discusses data for IMNN-001plus chemotherapy in advanced ovarian cancer.

Dr Lin on the Safety of NKTR-255 in Enhancing Immune Recovery Post-Chemoradiation in Locally Advanced NSCLC

November 15th 2024, 7:04pm

SITC Meeting

Steven H. Lin, MD, PhD, discusses the safety of NKTR-255 in enhancing immune recovery post-chemoradiation in locally advanced NSCLC.

Dr Weiss on the Role of Breast Imaging in Breast Cancer Treatment Decision-Making

November 14th 2024, 11:30pm

PER® Chemotherapy Foundation Symposium (CFS)

Anna Weiss, MD, discusses the significance of various imaging modalities in patients with breast cancer.